Part II of Ten Ten Ten’s seven-part Obesity Series is now live.

GLP-1 medications are genuine medical breakthroughs. They can produce significant weight loss, reduce cardiovascular risk, and improve the lives of people with clinical obesity. But they do not change the food system, built environment, or economic incentives that helped create America’s obesity crisis.

Approximately 12% of U.S. adults have taken a GLP-1 drug for weight loss. Yet U.S. list prices can exceed $1,000 per month, access remains deeply unequal, and many patients regain weight after discontinuing treatment.

Part II examines both sides of the GLP-1 revolution: the extraordinary clinical promise and the danger of treating a systemic crisis solely as an individual medical problem. These medications are an important part of the solution, but they cannot substitute for changing the conditions that continue to drive obesity.

Read Part II of VII: GLP-1s: Symptom Treatment vs. Systems Change. (https://substack.com/@tententenorg/p-195808358)